Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Biofrontera's Cost of Revenue fell 58.07% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 10.41%. This contributed to the annual value of $18.6 million for FY2024, which is 6.67% up from last year.
  • As of Q3 2025, Biofrontera's Cost of Revenue stood at $2.0 million, which was down 22.60% from $2.6 million recorded in Q2 2025.
  • Biofrontera's Cost of Revenue's 5-year high stood at $17.5 million during Q4 2022, with a 5-year trough of -$1.4 million in Q4 2023.
  • Moreover, its 3-year median value for Cost of Revenue was $4.3 million (2024), whereas its average is $4.1 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 9,554.70% in 2022, then plummeted by 107.76% in 2023.
  • Quarterly analysis of 5 years shows Biofrontera's Cost of Revenue stood at $181,000 in 2021, then spiked by 9,554.70% to $17.5 million in 2022, then plummeted by 107.76% to -$1.4 million in 2023, then surged by 488.72% to $5.3 million in 2024, then plummeted by 58.07% to $2.0 million in 2025.
  • Its Cost of Revenue stands at $2.0 million for Q3 2025, versus $2.6 million for Q2 2025 and $3.3 million for Q1 2025.